Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in miceMore about Open Access at the Crick
Authors listCamila H Coelho Pedro Henrique Gazzinelli-Guimaraes Jennifer Howard Emma Barnafo Nada AH Alani Olga Muratova Ashley McCormack Emily Kelnhofer Joseph F Urban David L Narum Charles Anderson Jean Langhorne Thomas B Nutman Patrick E Duffy
Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection.